# Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

> **NCT03734198** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **French Innovative Leukemia Organisation** · enrollment: 29 (actual)

## Conditions studied

- Relapsed or Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03734198
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-19
- **Primary completion:** 2023-06-17
- **Final completion:** 2025-12-19
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03734198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03734198, "Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03734198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*